KRAS and non-small cell lung carcinoma: MET amplification is also recognized as a resistance driver to RET‐specific inhibitors (selpercatinib), ALK inhibitors (alectinib), and KRAS inhibitors (sotorasib) in NSCLC.84, 138, 139, 140